409 related articles for article (PubMed ID: 34964205)
1. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
Li S; Jiang F; Chen F; Deng Y; Pan X
J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
[TBL] [Abstract][Full Text] [Related]
2. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
3. METTL3-Mediated m
Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
[TBL] [Abstract][Full Text] [Related]
4. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
Zhao C; Ling X; Xia Y; Yan B; Guan Q
Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065
[TBL] [Abstract][Full Text] [Related]
5. METTL3 Mediated MALAT1 m6A Modification Promotes Proliferation and Metastasis in Osteosarcoma Cells.
Zhang Y; Xu Y; Qiu G; Luo Y; Bao Y; Lu J; Wang T; Wang Y
Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37897586
[TBL] [Abstract][Full Text] [Related]
6. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
Cao Y; Di X; Cong S; Tian C; Wang Y; Jin X; Zhao M; Zhou X; Li R; Wang K
Life Sci; 2023 Feb; 315():121359. PubMed ID: 36608868
[TBL] [Abstract][Full Text] [Related]
7. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of
Lung Cancer].
Zhang Y; Wang Y; Liu M
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
[TBL] [Abstract][Full Text] [Related]
8. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Potentiates Cell Apoptosis and Drug Sensitivity to Taxanes and Adriamycin in Breast Cancer.
Yu J; Jin T; Zhang T
Med Sci Monit; 2020 Jul; 26():e922672. PubMed ID: 32623440
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine-induced SVIL antisense RNA 1 restrains lung adenocarcinoma cell proliferation by destabilizing E2F1.
Hu Z; Zhu L; Zhang Y; Chen B
Bioengineered; 2022 Feb; 13(2):3093-3107. PubMed ID: 35068325
[TBL] [Abstract][Full Text] [Related]
11. LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription.
Xiu B; Chi Y; Liu L; Chi W; Zhang Q; Chen J; Guo R; Si J; Li L; Xue J; Shao ZM; Wu ZH; Huang S; Wu J
Mol Cancer; 2019 Dec; 18(1):187. PubMed ID: 31856843
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
[TBL] [Abstract][Full Text] [Related]
13. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
14. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
Zhang Z; Fu J; Zhang Y; Qin X; Wang Y; Xing C
BMC Gastroenterol; 2023 Jun; 23(1):217. PubMed ID: 37344779
[TBL] [Abstract][Full Text] [Related]
15. METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma.
He F; Ren T; Tang X
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):193-197. PubMed ID: 37605570
[TBL] [Abstract][Full Text] [Related]
16. m6A Writer METTL3-Mediated lncRNA LINC01125 Prevents the Malignancy of Papillary Thyroid Cancer.
He T; Xia H; Chen B; Duan Z; Huang C
Crit Rev Immunol; 2023; 43(3):43-53. PubMed ID: 37824376
[TBL] [Abstract][Full Text] [Related]
17. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
18. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
19. METTL3-Mediated lncRNA m
Song Y; Pan Y; Wu M; Sun W; Luo L; Zhao Z; Liu J
Stem Cell Rev Rep; 2021 Dec; 17(6):2276-2290. PubMed ID: 34505967
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
